Form 4: Stoke Therapeutics' Chief Medical Officer Exercises Options and Sells Shares
SEC Form 4
Chief Medical Officer of Stoke Therapeutics, Barry Ticho, exercised stock options and sold 10,000 shares of common stock on August 1, 2024, according to a Form 4 filing.
Summary
- Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $0.60 per share on August 1, 2024.
- Simultaneously, Ticho sold 10,000 shares of common stock at a weighted average price of $14.5843 per share, with individual sales ranging from $14.18 to $14.94.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 14, 2023.
- Following these transactions, Ticho directly owns 2,485 shares of Stoke Therapeutics common stock and holds options for 40,000 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing trading plan. There is no indication of positive or negative implications for the company.
Positives
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although the pre-planned nature of these sales mitigates this risk.
Industry Context
Form 4 filings are a routine part of the US market and are required when company insiders trade their own company's stock. This filing provides transparency into the transactions of Stoke Therapeutics' Chief Medical Officer.
Comparison to Industry Standards
- Executive compensation packages often include stock options as incentives.
- Rule 10b5-1 trading plans are a common tool used by corporate insiders to sell shares in a planned and transparent manner, avoiding accusations of insider trading.
- The size and frequency of insider transactions are company and individual specific.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the sale of shares by a company executive, but the pre-planned nature of the sales mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| 2018-10-02 | Initial vesting date for the stock option (1/4th of the total award). |
| 2023-09-14 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2024-08-01 | Date of the reported transactions (option exercise and share sale). |
| 2028-04-02 | Expiration date of the stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.